Skip to main content
Premium Trial:

Request an Annual Quote

VitaGenomics License Affy s Arrays to Develop In Vitro Dx

NEW YORK, Dec. 27 (GenomeWeb News) - Affymetrix granted Vita Genomics non-exclusive access to its microarray technology to develop and market in vitro diagnostics, the companies announced jointly yesterday.

 

Shanghai GeneCore BioTechnologies, a fully owned subsidiary of Vita Genomics, licensed the technology under the "Powered by Affymetrix" program. The program allows companies to license Affymetrix's microarray products such as the GeneChip System 3000Dx.

 

Vita Genomics will develop in vitro tests to detect alpha interferon treatment response in patients with HBV and HCV as well as for early onset and allergic asthma in infants and young children.

 

Vita Genomics will incorporate Affymetrix's arrays into its molecular diagnostic assays.

 

Financial details were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.